| Single-cell technologies have contributed to unravelling tumour heterogeneity , now considered a hallmark of cancer and one of the main causes of tumour resistance to cancer therapies. Liquid biopsy (LB), defined as the detection and analysis of cells or cell products released by tumours into the blood, offers an appealing minimally invasive approach that allows the characterization and monitoring of tumour heterogeneity in individual patients. Here, we will review and discuss how circulating tumour cell (CTC) analysis at single-cell resolution provides unique insights into tumour heterogeneity that are not revealed by analysis of circulating tumour DNA (ctDNA) derived from LBs. The molecular analysis of CTCs provides complementary information to that of genomic aberrations determined using ctDNA to fully describe many different cellular components (for example, DNA , RNA , proteins and metabolites) that can influence tumour heterogeneity.
Precision medicine is still a realistic vision in medical oncology but tumour cell heterogeneity represents a substantial hurdle 1 . Many factors contribute to tumour heterogeneity, and tumour heterogeneity affects multi ple biological processes relevant to tumour evolution. Tumour heterogeneity is frequently seen as the result of genetic evolution but additional mechanisms such as epigenetic modifications, transcriptional changes and alterations in protein levels or protein modifications in the tumour cells and/or the microenvironment also play a major role 2 .
In principle, both temporal and spatial hetero geneity are the result of tumour progression. Temporal hetero geneity is the result of progression from local ized to meta static disease and is characterized by an intrapatient heterogeneity between the primary tumour and meta static lesions (for example, patients with HER2 -(also known as ERBB2 -) primary breast carcinomas can present with HER2 + metastases 3 ). Minor subclones irrelevant for the growth of the primary tumour in the original tissue can become dominant if they confer a survival advantage during metastatic dissemination and colonization of distant organs 4 . Spatial heterogeneity is characterized by the presence of different tumour clones in different regions of the primary tumour or between metastatic lesions in different tissues of the same patient 4 , which in metastatic lesions might be the result of different "seeds" released by the primary tumour and/or spe cific adaptation processes of disseminated tumour cells (DTCs) colonizing different distant sites. For example, the microenvironment conditions of the brain differ substantially from those conditions in the lungs or bones.
This complex biology results in a substantial degree of heterogeneity, which requires an indepth analysis of the primary tumour and comprehensive sampling of each metastatic lesion by multiple and repeated tissue biopsies 4 . However, this is not feasible in clinical practice as tissue biopsies are limited to very few sampling time points and accessible sites, and as frequent sites of metastasis such as the lungs, bones or brain are very difficult to biopsy.
An alternative strategy to understand heterogeneity might be liquid biopsy (LB), a diagnostic concept in oncology introduced approximately 10 years ago 5 , which refers to the analysis of tumour cells and tumourderived products present in body fluids (Box 1). LB analytes can derive from primary tumour, overt metastases or micrometastases in lymph nodes or at distant sites. Molecular characterization of circulating tumour cells (CTCs) was initially performed on enriched fractions 6, 7 , which provide only very limited information on tumour heterogeneity. Indeed, as minor subclones might be more difficult to detect in CTCenriched fractions that also carry a variable amount of leukocytes, isolation of single CTCs is therefore the method of choice to interro gate tumour heterogeneity. With the recent advances in technologies for singlecell analysis made during the past 5 years (Boxes 2,3), analyses of CTCs at singlecell resolu tion in peripheral blood could offer a unique minimally invasive approach to characterize and monitor dynamic changes in tumour heterogeneity in individual patients Disseminated tumour cells (DTCs) . A fraction of circulating tumour cells that have extravasated through the endothelium of the blood vessels at distant sites.
Micrometastases
A small collection of tumour cells that have metastasized from the primary tumour in different organs and that are not clinically detectable.
with cancer at the genomic, transcriptomic, proteomic and functional levels. Besides CTCs, circulating tumour DNA (ctDNA) analysis has been widely used to trace genomic tumour evolution during cancer therapy, through extensive sequencing efforts to assess genetic hetero geneity 8 . In addition, other tumourderived products also present in blood plasma, such as cellfree microRNAs (miRNAs), extracellular vesicles (EVs) or tumoureducated platelets, have attracted attention as LB analytes with potential clinical significance [9] [10] [11] .
Here, we will review how the characterization of CTCs at singlecell resolution provides insights into the biology and heterogeneity of cancer metastasis and highlight the challenges imposed by tumour hetero geneity for the clinical applications of CTC analysis. The technical hurdles linked to singleCTC isolation and subsequent molecular characterization are also described (Boxes 2,3).
Insights into heterogeneity from CTCs
The detection of tumour cells in peripheral blood offers a unique noninvasive opportunity to understand how this particular step in the tumour dissemination process can contribute to tumour heterogeneity. Genotypic and phenotypic characterization of CTCs at singlecell reso lution shows a substantial heterogeneity that can help to better understand the biology of tumour evolution.
Different routes of tumour cell dissemination contribute to heterogeneity. CTC detection in mouse models has contributed to better understanding of the complexity of metastatic spread directions, which could influence the development of heterogeneity. Dissemination of tumour cells from the primary lesion is usually depicted to occur through the lymphatic vessels into regional lymph nodes 12 or through the blood vessels directly to distant sites such as the lung, liver, brain or bones 13, 14 . However, two recent studies using genetically engi neered mouse models of mammary carcinoma demon strated that both routes of dissemination can occur together. Tumour cells can invade blood vessels within a lymph node, exit the node by entering the blood circu lation and then proceed to disseminate and colonize the lung 15, 16 (Fig. 1 ). This new potential route for metastatic spread brings interesting elements to the longstanding debate on the roles of lymph nodes in cancer progres sion by suggesting potential seeding of distant meta stases from regional lymph nodes 17 . These results also launch new interesting avenues for minimally inva sive detection of tumour dissemination in patients with affected lymph nodes [18] [19] [20] . Moreover, pioneering work showed that tumour cell dissemination is not necessarily a unidirectional process from the primary tumour to lymph nodes and/or distant sites, as CTCs could recirculate back to their original site of tumour growth, a phenomenon called tumour selfseeding 21 . CTCs as precursors of leptomeningeal metastasis were also recently reported in patients with medulloblas toma 22 , supporting the hypothesis that bloodbased tumour cell dissemination might also contribute to locoregional dissemination, as previously suggested in ovarian cancer 23 . Experiments in mouse models therefore converge towards the possibility of bidirec tional tumour cell exchange between anatomically sepa rated tumour masses, as another dynamic component of heterogeneity.
Tumour cells can enter the vasculature through interaction with a tumour microenvironment of metas tasis (TMEM) in the primary tumour that promotes tumour cell intravasation into the vessels 14 . However, it cannot be ruled out that there is also random access of tumour cells to the circulation leading to a sub stantial heterogeneity in the resulting population of CTCs. Vascularity of the tumours and organspecific vascular wall composition are anatomical factors to be considered 24 that can be affected by the presence of tumour cells as shown for the blood-brain barrier 25 . The blood-brain barrier seems to hinder the release of CTCs and ctDNA into peripheral blood, as indi cated by lower detection rates in patients with brain metastases compared with other metastatic sites 26, 27 . Nevertheless, CTCs can cross the blood-brain bar rier even in patients with primary brain tumours such as glioblastomas 28, 29 . The biological relevance of this route of dissemination in patients with glioblastoma is still disputed. The infrequent occurrence of extra cranial metastases might be the result of insufficient metastasisinitiating properties of CTCs or the short average lifespan of the patients diagnosed with this deadly tumour. Nevertheless, experimental data in a Box 1 | Liquid biopsy biomarkers assessed in blood of patients with cancer • Circulating tumour cells (CTCs): CTCs are released from primary tumours and metastases into the blood. CTCs can be enriched by label-dependent and label-independent approaches employing antibodies against cell surface antigens (for example, ePCAm) or physical capture devices. Downstream analysis of CTCs include molecular characterization at the DNA, RNA and protein levels and functional tests using cell culture or CTC-derived xenografts (CDXs). • Circulating tumour DNA (ctDNA): cell-free DNA (cfDNA) is released mainly through apoptosis or necrosis of tumour cells and normal cells but active secretion may play an additional role 26 . The majority of cfDNA in blood originates from haematopoietic cells 208 , but tumour-derived cfDNA (ctDNA) is present in very low concentrations (<5% to <0.1% of cfDNA) depending on the tumour type and stage 26 . ctDNA can be detected by sensitive molecular assays targeting mutations or structural genomic aberrations 8 . • Cell-free microRNA (miRNA) and other non-coding RNAs (ncRNAs): microRNAs (miRNAs) and small interfering RNAs (siRNAs) mediate post-transcriptional RNA silencing; small nuclear RNAs (snRNAs) regulate splicing; small nucleolar RNAs (snoRNAs) are involved in ribosomal RNA (rRNA), transfer RNA (tRNA), and snRNA processing; and P-element-induced-wimpy testis (piwi)-interacting RNAs (piwiRNAs) regulate chromatin modification and transposon repression 9 . miRNAs and other ncRNAs are released by tumour and host cells into the blood by apoptosis/necrosis or active secretion through extracellular vesicles (evs) or bound to plasma proteins 9 . • Extracellular vesicles: evs include all secreted or derived membrane vesicles shed by any type of cell and they function in cell-cell communication 202 . exosomes and microvesicles are the two major classes of evs that differ in their release mechanisms, size and content (miRNA, mRNA, DNA and so forth) 10, 209 . Development of better isolation methods for exosomes and the distinction between tumour-derived and host-derived evs are current topics of intense investigation 200, 210 . • Tumour-educated platelets: cross-communication between tumour cells and platelets plays a role in tumour progression 211 . Platelets can release RNA signalling complexes to other cells via microparticles (platelet-derived microparticles) that are estimated to account for around 70-90% of all evs 212 . Tumour cells can directly stimulate platelet protein synthesis and platelet signalling in a process called tumour education 211 , which has been exploited as a liquid biopsy biomarker 11,201 . mouse glioblastoma model showed that CTCs possess a cancer stem celllike phenotype and contribute to local tumorigenesis and recurrence by tumour selfseeding 30 . Thus, it can be speculated that brain tumour cells might be well adapted to the particular microenvironment of the brain, whereas they might have a reduced plasticity to adapt to the microenvironment conditions of extra cranial organs. Overall, it is still unclear whether all organ sites release CTCs in the same frequency and to what extent the tumour microenvironment (for example, through extracellular matrix stiffness or cooperation between tumour and stromal cells) plays a role in determining the CTC release rate 31 .
Heterogeneity in blood-based dissemination through single-cell analysis of CTCs.
Another substantial cause for CTC heterogeneity is the versatile repertoire of invasion and dissemination strategies that cancer cells utilize. Tumour cells can either disseminate as individ ual cells, for example via mesenchymal or amoeboid singlecell migration, or by collective migration as clus ters, in which cell-cell adhesion remains intact 32 (Fig. 1) .
Conversely, these different mechanisms of dissemination may also contribute to tumour heterogeneity. The most wellcharacterized mechanism of dissem ination is single cell. The contribution of epithelial tomesenchymal transition (EMT) in the acquisi tion of an aggressive and motile phenotype has been widely reported but led to controversy regarding CTC enrichment methods that are based on the capture of epithelial antigens such as epithelial cell adhesion mol ecule (EPCAM) (Box 4). In addition to EMT, a second type of motility shift has been described as essential in tumour progression, that is, mesenchymal-amoeboid transition 33 . Amoeboid singlecell migration is typical of myeloid leukaemia and lymphoma cells, smallcell lung carcinoma and smallcell prostate cancer 32 and was recently observed in melanomas 34 . Whereas mes enchymal migration is driven by actin polymerization (driven by RAC activity) and requires integrinbased cell-extracellular matrix adhesion and activity of matrix metalloproteinases, amoeboid migration is independ ent of proteolytic matrix degradation and adhesion to the extracellular matrix but requires enhanced cell contractility (driven by RHOA activity) 35, 36 . Amoeboid migration is faster than the mesenchymal mode 37 and coincides with proliferation, stemness and metastatic formation [38] [39] [40] . Why, how and when CTCs switch from one mode to another might be valuable subjects for future investigations.
The biology of CTC clusters is an emerging field of research. Clustered CTCs in peripheral blood have been reported in patients with different cancer types, but at lower frequencies than single CTCs [41] [42] [43] , whereas within primary lesions of epithelial tumours, collective migra tion is more prominent than singlecell motility 44, 45 . Clusters might be preformed before entering the blood or they might aggregate within the bloodstream 46 . The fact that clusters are infrequent in peripheral blood par ticularly in patients with earlystage cancer is consistent with the observation that clusters might be trapped in the small capillaries of the lungs and distant organs 41 and more easily trapped in narrow blood vessels and able to extravasate through capillaries 47 .
The implication of EMT in CTC cluster formation is still not well understood. In a proofofprinciple study on two patients with breast cancer, clusters strongly positive for mesenchymal markers and weakly positive for epithelial markers were described 48 . However, other papers suggest a high expression of genes encoding cell-cell junction proteins in CTC clusters. For example, RNA sequencing of matched CTC clusters and single CTCs unravelled 31 CTCclusterassociated genes, among which the gene encoding the junctional protein plakoglobin appeared to be essential for cluster forma tion 41 . Additionally, a lineagetracing tumour model revealed a programme of EMT conserved across several carcinomas, involving a relocalization of epithelial pro teins rather than transcriptional repression 49 . This alter native programme leads to a partial EMT phenotype that promotes collective tumour cell migration and forma tion of CTC clusters 49 . The DNA methylation landscape of single CTCs and CTC clusters revealed that binding sites for transcription factors associated with stemness (OCT4, NANOG, SOX2 and SIN3A) and proliferation are specifically hypomethylated in CTC clusters, and therefore are transcriptionally activated 50 . Importantly, the authors establish a link between elevated expression of cell-cell junction components and the ability to retain stemlike features that facilitate metastasis initiation. Interestingly, US Food and Drug Administration (FDA) approved compounds were able to dissociate CTC clus ters, leading to a decrease in metastasis formation 50 . In a separate study, a connection between cellular junctions and stemness within clusters was suggested. The stem ness marker CD44 mediated intercellular CD44-CD44 homophilic protein interactions implicated in cell cluster
Box 2 | Isolation of single circulating tumour cells
Studying circulating tumour cells (CTCs) at the single-cell level requires three main steps: enrichment, single cell detection and molecular characterization. Some molecular characterization methods such as immunocytochemistry or fluorescence in situ hybridization (FISH) require no single cell isolation to study CTC heterogeneity, whereas more in-depth single-cell analysis (for example, exome or RNA sequencing) requires the isolation of single CTCs or CTC clusters. methods to enrich CTCs are usually divided into antigen-dependent (for example, ePCAm-based) or antigen-independent (for example, size, deformability, density) methods 113, 213 . Starting from a concentration of one CTC in millions of nucleated blood cells, enrichment leads to fractions of single CTCs diluted in hundreds to thousands of blood cells.
After CTC enrichment, fluorescence-activated cell sorting (FACS), laser capture microdissection 214 or manual 28, 94, 215 and automated 216, 217 micromanipulation can be used to isolate single cells. These cumbersome technologies provide high flexibility for downstream applications and the possibility of selecting single cells based on morphology or protein marker expression, which allows assessment of heterogeneity of CTCs at the genomic and phenotypic level in individual patients. For example, using dielectropherisis (DeParray), the molecular characterization of single CTCs has unravelled mechanisms of resistance to AlK inhibitors in patients with non-small-cell lung cancer 216, 217 . Important considerations should be made while choosing a method for single-cell isolation such as the number of cells to sort, the criteria to sort the cells, the throughput of the device, the flexibility in the type of downstream analysis and the quality of the isolated cells for downstream analysis (see Box 3) . There might also be an advantage to merging enrichment technologies with high-throughput single-cell analysis in large integrated platforms. many different companies are also currently working on directly coupling sorting and downstream analysis 218 . formation and subsequent CD44-PAK2 interactions activated FAK signalling, another molecular pathway reported to play a role in cancer stem cells 46 .
CTCs can also cluster with nonmalignant cells pres ent in the bloodstream such as leukocytes or cotravel with stromal cells such as cancer-associated fibroblasts, both of which sustain the viability of CTCs in the blood stream 51 . Comparing the transcriptome profiles of CTCs in clusters with neutrophils against single CTCs revealed that clustering fosters the metastatic potential of CTCs through the induction of genes responsible for cellcycle progression 52 . Exploration of the crosstalk within CTC and polymorphonuclear myeloidderived suppressor cell (PMNMDSC) heterotypic clusters revealed that the Notch-Nodal signalling axis, driven by reactive oxygen species, is implicated in cell survival and meta stasis formation 53 . Tumour cells and inflamed neutrophils were also shown to form clusters trapped in the endo thelial glycocalyx; neutrophilderived IL8 increased the extravasation potential of adjacent tumour cells through modulation of the endothelial barrier 54 .
Overall, the phenotypic heterogeneity within clusters appears to convey a survival advantage for colonization at distant sites. Patients with clusters indeed have a worse prognosis 41, 42, 55, 56 . The genomic composition of CTC clusters would be interesting to study as it might also play a role for tumour heterogeneity. Cellular tagging and mixing studies in the mouse showed that almost all CTC clusters appear to be of oligoclonal origin, rather than being derived from the progeny of a single migratory cell 41 . A future challenge will be, for instance, to understand whether CTC clusters increase tumour heterogeneity in patients with cancer.
Phenotypic characterization of CTCs to identify metastasis-initiating cells. The identification of those
CTCs that initiate metastatic colonization at distant sites, that is, circulating cancer stem cells or metastasisinitiating cells, is of utmost importance. The phenotypes of CTCs should therefore be dissected in relation to their meta static competence. Some studies have established a link between EMT and the acquisition of stem cell properties 57 , and stem cell markers (for example, CD44) were enriched in a subpopulation of CTCs with mesenchymal traits in different tumour entities [58] [59] [60] , introducing another level of heterogeneity among CTCs. It would be important to further evaluate the prognostic role of CTCs expressing stem cell and EMT markers in patients with earlystage cancer and link the data to clinical outcome with regard to metastatic relapse 61 .
It has also been possible to unravel the molecular path ways involved in metastasis formation using CTC-derived xenografts (CDXs) or CTCderived cell lines. However, these models are still difficult to create and usually require very high levels of hundreds of CTCs in the blood sample that can be found only in a few advancedstage patients 62 or in patients with smallcell lung cancer (SCLC) who present, on average, with 10 times more CTCs than patients with other types of carcinomas 63, 64 . Nevertheless, CDXs have suggested potential phenotypes of metastasisinitiating cells in breast cancer, such as CTC populations expressing EPCAM, CD44, CD47 and MET (therefore bearing a hybrid, partial EMT pheno type) giving rise to bone, lung and liver metastases 65 or CTCs expressing HER2, epidermal growth factor recep tor (EGFR), heparanase and NOTCH1 as potential initiators of brain metastases 66 
. Comparing expression

Box 3 | Technical aspects of molecular characterization of circulating tumour cells at single-cell resolution
using the appropriate pre-analytical conditions, heterogeneity of single, captured circulating tumour cells (CTCs) can be assessed at the level of DNA, RNA, proteins and metabolites.
• DNA: characterizing the genome from a single CTC usually requires whole-genome amplification (WGA) to generate sufficient amounts of DNA template; however, WGA may produce technical artefacts, for example allele drop out, loss of coverage, decreased coverage uniformity or allelic imbalances 215, 219 . Third-generation sequencing methods now allow sequencing of non-amplified DNA molecules 220 and would in the future be beneficial for CTC analysis at single-cell resolution. Fluorescence in situ hybridization (FISH) allows direct visualization of a link between a particular CTC phenotype and genomic aberrations, and was first employed to evaluate the tumorous origin of circulating cells 221 . It could be applied directly to CTC-enriched fractions without the need to perform single-cell isolation to unravel their genetic heterogeneity. In situ DNA sequencing methods are also attractive in this sense 222 .
If sufficient amounts of DNA are available, recent technologies also permit the interrogation of heterogeneity of CTCs at the epigenetic level 223 , including by promoter methylation analysis 224, 225 , nucleosome positioning or higher-order chromatin conformation in single cells 225 . • RNA: single-cell RNA sequencing methods include reverse transcription, cDNA amplification and sequencing library preparation. Capture of highly expressed transcripts during reverse transcription and 3′ coverage biases are current limitations. After transcription, minute amounts of cDNA have to be amplified which can result in amplification biases; using unique molecular identifiers ("bar codes") during reverse transcription or spike-in of external mRNA improves the quality of mRNA analysis. most studies have been restricted to mRNAs although small non-coding RNAs represent another important level of regulation [226] [227] [228] . • Proteins: detection of multiple proteins in CTCs by immunocytochemistry remains challenging, mainly due to problems of sensitivity and cross-reactivity. Recently, a single CTC resolution western blot analysis allowed the simultaneous measurement of 12 proteins 229 , and the combination of flow cytometry with mass spectrometry can assess over 40 proteins at single-cell resolution 230 . Recently, imaging mass cytometry was integrated with high-definition single-cell analysis to interrogate more than 40 proteins in CTCs with the use of metal-conjugated antibodies 231 . • Metabolites: metabolic reprograming is a hallmark of cancer but remains difficult to study in a single cell due to its extreme dynamic and labile character 232 . However, fluctuations in pH or detection of lactate concentrations have been employed in a microfluidic device to identify putative CTCs without the need for surface-antigen labelling 233 . profiles of CTCenriched fractions associated with brain metastasis and CTC profiles associated with other metastatic sites in patients with breast cancer further confirmed the importance of Notch signalling for brain metastases 67 .
In colorectal cancer, CTCs expressing the thrombo poietin receptor showed a strong liver tropism as a conse quence of their enhanced lysine catabolism 68 , and genes regulating energy metabolism and DNA repair were suggested to be involved in the initiation and formation of metastasis 69 . Interestingly, transcriptomic analysis on enriched fractions of CTCs expressing the stemness marker CD44 in patients with breast cancer revealed a state of reduced metabolic and/or mitotic activity which might enable CTCs to survive in circulation 67 .
Protein ubiquitylation was identified as a regulatory pathway important for the metastasiscompetent state of bonemarrow DTCs from melanoma CDX 70 .
Overall, these examples highlight the potential of CDX or CTCderived cell lines to understand the onset of metastasis and identify new potential therapeutic strat egies. Importantly, these models might also be useful to study the natural or therapyinduced genomic evolution of the tumour and the development of heterogeneity providing they are representative of human tumours 71 .
However, other parameters can determine the hetero geneous pattern of metastases in patients with cancer 24 and some of these have been studied using CTCs. Mechanisms implicated in extravasation of CTCs have been explored in experimental studies: for example, The diversity of molecular mechanisms leading to tumour dissemination are mirrored by a substantial heterogeneity in the pool of circulating tumour cells (CTCs) present in the blood. There are multiple entry sites for cells into the blood (primary tumour, lymph node, metastasis) and molecular mechanisms implicated in invasion (epithelial-to-mesenchymal transition (EMT), mesenchymal-amoeboid transition (MAT), single or collective migration). The survival of CTCs in blood might be as single cells or clusters, and the interaction of CTCs with host cells (leukocytes, platelets) varies. Furthermore, extravasation to distant sites (for example, bones, lungs brain or liver) and the capacity to colonize these sites by forming overt metastases differ amongst CTCs. Disseminated tumour cells (DTCs) and tumour cells derived from micrometastases or overt metastases can also recirculate back into the bloodstream; to what extent this "recirculation" contributes to further metastatic spread or even local tumour recurrence in patients with cancer is the subject of ongoing investigation. A question mark indicates the processes that remain to be proven in patients with cancer. cfmiRNA , cell-free microRNA ; cfRNA , cell-free RNA ; ctDNA , circulating tumour DNA.
how CTC extravasation is affected by blood circulation patterns in different organs 72 , by the structure of tar get organ capillary walls 73 , by molecules playing a role in adhesion and rolling of CTCs 74 or by disruption of endothelial junctions 75 . In addition, the tropism of CTCs can be affected by tumour microenvironment "niches" that allow colonization and outgrowth of DTCs that need to adapt to these conditions 76, 77 .
Genotypic characterization of CTCs to understand tumour evolution. Tumour heterogeneity is considered "fuel" for tumour evolution and the emergence of resist ance mechanisms, and targeting this evolution has been envisioned as a therapeutic strategy 78, 79 . To date, compre hensive studies dealing with tumour heterogeneity have relied on analysing data from multiple biopsy sites. A key question, therefore, is whether genotyping of CTCs can be used to recapitulate tumour heterogeneity but this requires overcoming the challenges of CTC scarcity and of sequencing lowinput material. Indeed, many genomic studies have been performed on pooled frac tions of CTCs. For instance, in myeloma, bonemarrow tumour cells and CTCs appear to have similar clonal structures, and, interestingly, discordances restricted to subclonal mutations between bonemarrow tumour cells and CTCs were also found 80 . With the development of a sophisticated integrated process to isolate, qualify and sequence whole exomes of CTCs at singlecell reso lution with a high accuracy, single CTCs and multiple regions of the primary tumour were compared within two patients with prostate cancer 81 . This proofofconcept data illustrated that the mutation spectra of CTCs and overt metastases closely resembled those of one par ticular region of the primary tumour, which might be the potential metastasisinitiating area. In some cases, it might be easier to distinguish tumour heterogeneity from CTCs rather than primary tumours: for example, using diagnostic leukapheresis (DLA), analysis of hun dreds of CTCs unravelled a marked tumour heterogen eity including subclonal copynumber alterations (CNAs) that were not easily distinguished from bulk analysis of tumour biopsies 82 . Individual and pooled CTCs from patients with meta static breast cancer were recently sequenced for a panel of 130 genes. Comparison with their metastatic tissue counterparts revealed 85% concordance in at least one or more recurrent somatic mutations and CNAs 83 . Overall, these data support the notion that CTC sequencing can provide important information on heterogeneity and metastatic evolution, which might reveal vulnerabil ities that could be used to prevent or treat metastasis. Studies comparing primary tumours and metastases have revealed that metastatic spread can occur through multiple progression models (parallel progression and linear progression) and in different directions (from pri mary tumour to metastasis but also bidirectionally with selfseeding of the local site of tumour growth 21 ), within specific tumour types and even in individual patients with cancer 84 . These studies also converge towards the idea of a macroevolutionary shift characterized by large chromosomal aberrations or CNAs that appear during metastatic formation. In a recent pilot study, singlecell sequencing of CTCs revealed a convergent evolution of CNAs from primary tumour to CTCs, an argument supporting the idea that metastatic dissemination is not a random process 85 . In another study on patients with colorectal cancer, recurrent chromosomal aberrations were successfully identified and related to the different stages of the metastatic cascade by analysing the pres ence of CTCs in different blood compartments and the pattern of overt metastases in the liver and lungs 86 .
The enormous advances made in highthroughput sequencing methods have mainly highlighted ctDNA as a noninvasive biomarker able to recapitulate some of the branched subclone(s) seeding the tumour relapse in patients with nonSCLC (NSCLC) 64 or in patients with SCLC 87 . However, it has also to be acknowledged that a ctDNA sampling strategy could present some caveats in terms of providing a detailed phylogeny due to a potential overrepresentation of DNA from dying cells. Moreover, the low concentration of some ctDNA variants requires a substantial depth of sequencing combined with the need for multiplexing to encompass tumour heterogeneity, which is a technical challenge 2 .
At present, it is not clear to what extent genomic analyses of CTCs and ctDNA in the same patient might Box 4 | Circulating tumour cells and epithelial-to-mesenchymal transition epithelial-to-mesenchymal transition (emT) is often seen as a prerequisite to tumour dissemination 234 , which has motivated the development of assays that capture circulating tumour cells (CTCs) independent of the expression of epithelial cell surface antigens (for example, ePCAm), instead using physical differences between CTCs and the surrounding normal blood cells. Because classical mesenchymal markers such as vimentin or N-cadherin are also expressed on leukocytes, the discovery of new markers of the mesenchymal phenotype specific to tumour cells is also an important subject of CTC research. For example, the oncofetal chondroitin sulfate targeted by the VAR2CSA malaria protein and plastin 3 have been characterized as interesting antigens respectively able to capture and characterize mesenchymal CTCs 235, 236 .
To date, the precise role of emT for tumour cell dissemination and onset of metastases in patients with cancer is still not clear 234 . Despite the elegant work in experimental models, most clinical studies showing a link between CTCs and metastatic relapse have used epithelial markers such as ePCAm or keratins for detection and/or single-cell identification of CTCs 213, 237 . This fact supports the view that tumour cells with some degree of epithelial phenotype are relevant for survival of tumour cells in blood and subsequent initiation of metastasis 65 .
However, the presence of CTCs with mesenchymal traits have been reported 238 , and these CTCs have been linked to acquisition of resistance to therapy 48 or disease burden and clinical outcome in prostate cancer 239 , and their tumorigenic capacity has been illustrated for one patient with non-small-cell lung cancer 240 . moreover, genomic instability might be more prevalent within CTCs expressing mesenchymal markers in patients with metastatic breast cancer 241 , which generates an interesting hypothesis regarding the propensity of these CTCs to contribute to tumour heterogeneity.
variable intermediate states of emT exist on CTCs. Co-expression of mesenchymal and epithelial markers or different expression levels of genes involved in emT has been demonstrated by immunofluorescence 236, 240 , single-cell RNA expression 239 or promotor methylation analysis 224 . A recent study reported a gradient of increasing mesenchymal traits of CTCs during their journey from the primary lesion to distant sites in hepatocarcinomas 242 , corroborating the hypothesis that emT can be induced after CTCs enter the vasculature 243 . The observation that CTCs can bear a hybrid emT phenotype 48 is in line with the concept that emT is not a binary switch between two extreme states but rather a continuum of intermediate states 234, 244 .
Therefore, it is still unclear which subsets of CTCs (epithelial or mesenchymal) are more relevant for metastatic progression but most likely there is a continuum and heterogeneity of various emT spectra in individual CTCs. Thus, CTC capture assays should not assume either a mesenchymal or epithelial phenotype but the possibility of various intermediate stages.
Parallel progression
A model of progression implying that a metastatic clone leaves the primary tumour early and continues to evolve in parallel to the primary tumour.
Linear progression
A model of progression implying that cancer cells accumulate multiple successive rounds of mutation and selection for invasiveness within the primary tumour before metastasizing.
Convergent evolution
The recurrent tendency of a biological system to independently evolve similar traits arriving at the same solution.
www.nature.com/nrc provide complementary information on tumour hetero geneity and evolution. Enriched fractions of CTCs and ctDNA have been compared regarding their mutation content 88 or DNA methylation status 89 . In some cases, ctDNA and CTCs reported discordant results (that is, a mutation detected in CTCs and not in ctDNA, and vice versa) illustrating the complementarity of both analytes 88 . A recent pilot study on five patients with meta static breast cancer compared the mutational con tent of CTCs at singlecell resolution and ctDNA 90 . In all patients, ctDNA profiles provided an accurate reflection of mutations seen in individual CTCs 90 . Larger studies are required to further study in parallel, in the same patients, the information given by CTCs and ctDNA.
In CTCs, other important information can be found at the transcriptional level that has the potential to unravel the alteration of molecular pathways during tumour evolu tion. Indeed, breast and lung carcinomas from patients with and without DTCs in the blood or bone marrow display distinct expression signatures 91, 92 . In a pio neering singlecell study, CTCs from patients with breast cancer profiled for expression of 87 cancerassociated and reference genes showed remarkable intrapatient heterogen eity 93 . In addition, multimarker RNA profiling of CTCs at singlecell resolution has revealed distinct CTC subsets and provided important insights into gene regulatory networks relevant for tumour evolution in prostate cancer 94 . Singlecell RNA sequencing is one of the most advanced singlecell technologies and was recently used to show that CTCs recapitulate the transcriptional status of the bone marrow disease in multiple myeloma 95 .
Clinical challenges for LBs
We will discuss here the challenges of CTC and other LB analytes for the different clinical applications (Fig. 2) with emphasis on limitations derived from tumour heterogeneity and evolution.
Early detection of cancer.
Early detection of small localized tumours can allow cure by surgical resection or radiotherapy. Screening tests so far available are applied to enriched populations that are restricted by age (for example, colonoscopy for colorectal cancer) or gender (for example, prostatespecific antigen testing in men), or to individuals with an increased risk of devel oping cancer such as family members of BRCA mutation carriers (that are prone to developing breast or ovarian cancer) or patients with chronic obstructive pulmonary disease at increased risk of developing lung cancer 96 . LB analytes have the potential to allow screening for multiple tumour types in a broad group of individuals at risk to develop cancer. The primary tumour is illustrated as heterogeneous; such heterogeneity typically occurs at all other stages as well. Relative changes in the amounts of blood volume necessary to detect circulating tumour cells (CTCs) in the different phases of tumour development and progression are presented in the graph, which also notes the key aim of the clinical applications at the different stages of tumour evolution. We assume that the burden of CTCs at relapse is higher than at initial diagnosis because autopsy studies have shown that patients clinically diagnosed as having one or few metastatic lesions in fact harbour a much higher tumour burden of clinically occult micrometastases or overt metastases 249, 250 . This is also consistent with the fact that the CTC counts in patients with metastatic cancer are higher than in patients at primary diagnosis without clinically detectable distant metastases [251] [252] [253] [254] . Diagnosis leukapheresis (DL A) can be used to estimate the number of CTCs in the total blood volume of patients with cancer 169, 255 . The blood sampling volume needed to detect CTCs can be calculated from the frequency distribution of CTCs in patients with metastatic cancers 256 . DTC, disseminated tumour cell.
The use of CTCs for early detection is probably very limited by the low detection rates in earlystage cancer. Here, ctDNA (or other LB analytes) that occur at higher concentrations in blood plasma have more potential, unless the sensitivity of CTC detection can be increased considerably (Box 5) . This limitation also holds true for ctDNA analyses, however. Besides the detection of ctDNA in virusinduced cancers (for example, human papilloma virus 97 , Epstein-Barr virus 98 ), ctDNA derived from most tumour entities frequent in Europe and the United States (for example, breast, lung, colorectal and prostate cancer) presents at a mutant allele frequency of about 0.1% of cellfree DNA (cfDNA) or lower in blood plasma at initial tumour diagnosis [99] [100] [101] . Thus, highly sen sitive methods and sufficient plasma volumes are needed to interrogate minute amounts of ctDNA [102] [103] [104] [105] .
Tumour heterogeneity can arise from somatic mosai cism -that is, the accumulation of mutations during development and ageing -which leads to the genera tion of cells with different genotypes in the same indi vidual 106 . Advances in genome sequencing during the past few years have demonstrated that the prevalence of cancerassociated variations is close to 100% in aged individuals (that is, those over 50 years old) 107 . Somatic mutations are frequently detected in leukaemia genes from cfDNA in aged individuals who do not have can cer 108, 109 , and TP53 mutations in cfDNA occur at very low allelic fractions in 11.4% of individuals who do not have cancer 110 . These observations emphasize the need for a better understanding of the boundaries between ageing and early cancer development and the limits of cfDNA based mutational analysis for early detection of cancer.
Association of mutational analysis with other features of cfDNA such as fragmentation patterns might be a promising strategy to improve early cancer detection 111 .
Another hurdle in early detection is the consider able genetic heterogeneity of most solid cancer types. An early detection assay must therefore encompass a wide possible range of genomic aberrations (for example, DNA mutations and structural changes), and may also need to include other variables. For example, com bined ctDNA analysis of 1,933 mutations on 16 differ ent cancerassociated genes for detection of earlystage cancers (that is, no clinical signs of distant metastasis, stage I-III) of diverse origins with the levels of eight protein markers in blood plasma allowed detection of ovarian cancer with high sensitivity, whereas the detec tion of breast cancer was only feasible in 33% of patients 112 . CTCs might become useful in early detection if the sen sitivity of CTC detection can be increased considerably by the use of much higher blood volumes or in vivo devices (Box 5) . If this could be achieved, one could envi sion a place for CTCs in early detection, which might be potentially more reliable than cfDNA as it would not be hampered by ageingassociated DNA mutations and might represent intact viable tumour cells rather than "signals" from dying tumour cells releasing their DNA.
Risk stratification. Prognostic information inferred from CTC enumeration at the time of primary diagnosis and surgery is well established in breast cancer but larger clinical studies have shown similar results in various other solid tumours including bladder, colorectal, lung, testicular, and head and neck cancer 113 . Studies on pheno typing or genotyping of CTCs in earlystage disease are scarcer 18, 20, 114, 115 than in metastatic disease due to the very low number of CTCs available for downstream molecular analysis. Recently, the expression of epithe lial, mesenchymal and cancer stem cell markers was assessed in CTCenriched blood fractions from patients with earlystage breast cancer 61 . CTCs with epithelial, epithelial and mesenchymal, or mesenchymal markers were detected at a similar rate but only mesenchymal CTCs were associated with a significantly higher risk of death 61 . Genotyping is also possible on cfDNA and the prognostic value of ctDNA mutation detection has been shown in smaller studies 116 including the TRACERx landmark study in earlystage NSCLC 64 and in patients with stage III melanoma 117 .
Comparing the prognostic value of CTC and ctDNA would help to understand the extent to which these two biomarkers are complementary. The parallel eval uation of these two LB analytes has revealed differential prognostic value in patients with metastasis 118, 119 .
Early detection of relapse. Following surgical removal of the primary lesion and possibly radiotherapy and adju vant systemic therapy, monitoring the blood for signs of metastatic progression can be used for following tumour evolution and early detection of relapse and/or thera peutic resistance. Here, the information derived from the primary tumour analysis, such as the histological Box 5 | Strategies for the improvement of circulating tumour cell capture rates enormous advances have been made in technologies for enrichment of circulating tumour cells (CTCs) from a single blood draw with the development of a myriad of different approaches 113, 213 . However, the low concentration of CTCs in blood particularly in patients with early-stage cancer remains a major obstacle, which might be overcome by increasing the blood volume available for CTC capture using two principal approaches:
• Diagnosis leukapheresis (DLA): leukapheresis is a standard clinical procedure to isolate large amounts of peripheral blood mononuclear cells (PBmCs) that has various applications, most notably stem cell harvest. Practically, leukapheresis is based on continuous centrifugation that collects approximatively 2.5 billion (that is, 2.5 × 10 9 ) PBmCs from 2.5 l of blood; PBmCs have a density of 1.055-1.08 g ml -1 , which is supposed to be similar to the density of tumour cells. DlA has been successfully applied to detect large amount of CTCs even in metastasis-free patients 214 . However, the large number of PBmCs that are also collected requires the development of new technologies for large-scale enrichment of CTCs 215 . • In vivo devices: an alternative approach to increase the blood volume for CTC analysis is the use of in vivo devices to continuously collect CTCs directly from a peripheral vein of a patient with cancer. Proof-of-principle studies on patients with cancer have been published for a structured medical wire coated with an ePCAm antibody that is placed for 30 min in the peripheral vein of a patient; however, the enrichment advantage over conventional ex vivo enrichment was less pronounced than expected 150, 170 . An original approach based on the photoacoustic detection of melanin allowed the detection of tumour cells in patients with melanoma with unprecedented sensitivity 245 . Further development is needed to recover the detected CTCs in order to perform downstream analysis. more recent developments have also been reported in animal models, but validation of these technologies is needed in patients with cancer. large amounts of CTCs have been captured in a porcine model by injecting antibody-coated magnetic particles into the veins, which then label CTCs in situ 246 . Another method used an indwelling intravascular aphaeretic system based on a microfluidic ePCAm-coated chip in a canine model 247 , and a third used an optofluidic system that continuously collects fluorescently labelled CTCs from a mouse model for several hours per day or over multiple days or weeks 248 .
www.nature.com/nrc type and molecular signature, is currently used to design patientspecific assays 64, 120 . However, natural tumour evo lution and therapyinduced selection (for example, CTCs expressing mesenchymal markers might be selected during chemotherapy 48 ) can lead to substantial quanti tative and qualitative changes in the mutation spectra and pheno type of tumour cells (discussed above). Thus, tumour clones harbouring driver mutations that conferred a growth advantage at the primary site might no longer be relevant for the survival of CTCs in blood and the subse quent colonization of distant metastatic sites 121 , illustrat ing the clinical relevance of monitoring residual disease with LBs. Nevertheless, promising clinical data have been published using CTCs detected 2 or 5 years after adjuvant therapy in breast cancer 18, 20, 122 or ctDNA in colorectal cancer 123 for surveillance and to indicate relapse before metastatic tumour relapse is evident from imaging 113 .
In future studies, the combined molecular characteriza tion of CTCs and ctDNA could provide complementary information, and it would also be interesting to assess whether detection of ctDNA and/or CTCs (or even CTCs bearing a specific phenotype) provides more accurate clinical information on tumour evolution in individual patients. A good example is the use of CTCs and ctDNA as companion diagnostics in patients receiving immune checkpoint inhibition therapy (see below).
Identification of the tissue of origin of CTCs and ctDNA.
In cases where the location(s) of the primary tumour or metastases is unknown, identification of the tissue of origin to determine the anatomical location of the primary tumour, micrometastasis or metastasis is very important to direct medical imaging and tissue exami nation. Analysis of genomic patterns in CTCs has been investigated for identification of the metastatic organ site 124 . Few genomic signatures have been associated with any particular site of metastasis development 92, 125 ; therefore, expression signatures seem more likely to provide sitespecific information from CTCs. Tumour cells lodging in a particular site may show a specific expression pattern induced by the crosstalk with the microenvironment 91, 126 . Characterizing a CTC fraction from patients with metastatic breast cancer confirmed this hypothesis and highlighted the Notch pathway and immunomodulatory (tumour necrosis factor (TNF), IL1β and nuclear factor κB (NFκB)), inflammatory (the chemokine CXCL8, the chemokine receptor CXCR4 and CD86) and mitogenic (plateletderived growth fac tor BB (PDGFBB))activated pathways as a signature of CTCs associated with brain metastasis 67 . Moreover, a comparison of breast cancer cases with bone versus visceral organ progression indicated that activation of androgen receptor (AR) signalling in CTCs is associated with breast cancer that predominantly metastasizes to bone, which opens new therapeutic opportunities 127 . Tumours present specific methylation patterns that can be detected in cfDNA [128] [129] [130] . The largescale analy sis of epigenetic alterations such as methylation of CpG islands 131 might be a promising approach but is techni cally demanding if only minute amounts of tumour cells or DNA molecules are available. A seminal example of the usage of cfDNA methylation is the FDAapproved SEPT9 test developed to detect colorectal cancer, mostly indicated for the patients in the United States who are unwilling or unable to be screened by recommended methods 132 . To overcome constraints linked to DNA damage induced by bisulfite conversion, enrichment based on cellfree methylated DNA immunoprecipita tion and highthroughput sequencing was developed; this allowed genomewide bisulfitefree plasma DNA methylation profiling of small quantities of cfDNA 133 . Other seminal studies have shown the possibility of mapping nucleosome occupancy to infer expressed or silent genes via cfDNA analysis and thereby deduce the tissue of origin of the metastatic tumour lesion 134, 135 . However, the genome must be analysed in great depth, which limits the use of this method to patients present ing with a high amount of ctDNA. An approach using genomewide analysis of fragmentation patterns was recently developed to detect a large number of abnor malities in cfDNA, with the aim of increasing the detec tion sensitivity when only minute amounts of cfDNA are available 111 . Analysis of fragmentation patterns was able to distinguish patients with cancer from healthy donors and to identify the tissue of origin of cancer by applying machine learning methods 111 .
In the future, both approaches (CTCs and ctDNA) could be combined to increase the precision of the infor mation obtained. For example, one could envisage that, initially, ultrasensitive ctDNA analysis helps to identify subjects at risk of having primary or relapsed cancer, and, then, the more cumbersome DLA might be used to capture high amounts of CTCs for more indepth analy sis of tumour location as well as therapeutic targets and resistance mechanisms.
Identification of therapeutic targets and resistance mechanisms.
Precision oncology aims at treating patients according to the molecular changes that are present in their tumours, and adjusting this over time as tumours evolve. Monitoring treatment effects by sequential tis sue biopsies is difficult and, in some cases, impossible to introduce into clinical practice. Here, we will illustrate how analysis of blood for CTCs and other LB analytes can reveal mechanisms of resistance to cancer therapies. Most of the studies have been performed in patients with metastatic disease who have higher CTC counts and ctDNA concentrations than patients in the early stages or who have not yet relapsed.
Resistanceconferring mutations in oncogenes have been identified as a major source of intrinsic and acquired resistance and can be studied from captured CTCs to monitor tumour evolution upon therapy pres sure 136, 137 with the potential advantage of singlecell analy sis to identify proper clones. Serial ctDNA analy sis in patients with colorectal cancer or NSCLC under going treatment with EGFR blockade have demonstrated that ctDNA analysis could be an alternative efficient approach to identify resistanceconferring mutations in KRAS or EGFR 138, 139 . Notably, the detection of the EGFR mutations in NSCLC by the Cobas EGFR Mutation Test 2 has been approved by the FDA. In contrast to targeted approaches, broadcoverage sequencingbased approaches (for example, exome sequencing) require
Bisulfite conversion
A technique used to study DNA methylation. Following bisulphite treatment, cytosine is converted into uracil but methylated cytosine is left intact.
NATuRe RevieWS | CANCER R e v i e w s volume 19 | oCToBeR 2019 | 561 higher ctDNA levels (>2-5% mutant allele fraction) and are usually only possible in patients with advanced disease 140, 141 . Unexpectedly, patients with metastases sometimes present with low fractions of ctDNA 142, 143 , which suggests that further investigations on mecha nisms involved in the release, stability and clearance of ctDNA into the blood are required. Nevertheless, ctDNA profiling has allowed the successful detection of concomitant resistanceconferring mutations residing in separate metastases in a patient with breast cancer 144 , and in another patient with colorectal cancer 145 as well as in patients with melanoma 146 , suggesting that the blood contains a suitable diagnostic pool of ctDNA released from tumour lesions at different locations in the host. Importantly, there is today no consensus between the different ctDNA panel assays because of different assay performance characteristics (limits of detection, inter rogation of different genomic regions), and the field would therefore benefit from crossassay comparisons 147 . We also need to know more about the release of ctDNA from tumour cells. The size distribution of ctDNA frag ments in blood plasma indicates that the majority of DNA is released from apoptotic cells, which may limit the power to measure signatures from surviving tumour clones resistant to therapy 148 . This is an important limi tation if the ctDNA signature is used to switch therapy in patients with cancer. A combined analysis of the DNA and RNA content of EVs with cfDNA detection was reported to increase the sensitivity of detection of EGFR mutations in patients with NSCLC and to pre dict response to a thirdgeneration EGFR inhibitor 149 . EVs are released from viable cells and therefore their DNA might reflect the genomic aberrations of viable tumour cells. Thus, analysis of EVs could add important information on therapyresistant tumour clones.
To date, few studies have compared CTCs and ctDNA regarding the detection of mutations associated with resistance. The EGFRT790M resistance mutation was detected slightly more often in ctDNA than in CTCs; however, the two assays together allowed a success ful genotyping in all patients, revealing their comple mentarity in patients in which tumour biopsy was EGFRT790Mnegative or indeterminate 137 . Detecting mutations in CTCs requires more technical efforts than ctDNA analysis but has additional benefits, such as correlation with a specific transcriptomic, protein or morpho logical phenotype 113 . A connection between drug resistance and CTCs expressing mesenchymal markers has already been indicated in patients with breast or prostate cancer 48, 150 . Therefore, it would be interesting to monitor the genetic aberrations of CTCs with cancer stemness phenotypes during systemic cancer therapy. Preclinical models suggest that residual disease could harbour a small population of quiescent drugtolerant cells that have survived initial therapy due to adaptive activation of alternative molecular pathways and that could lead to de novo generation of resistance alterations 138, 151 . Molecular characterization of CTCs at singlecell resolution could help to identify and analyse these drugtolerant persisters.
Detection of rearrangements in plasma is more chal lenging than identifying short variants such as point mutations and insertions/deletions, and requires broader approaches 26, 152 . Genomic rearrangements, notably rearrangements of the ALK or ROS1 receptor tyrosine kinases, are therapeutic targets of crizotinib in NSCLC, and they have been inferred from CTC analyses 153, 154 and more recently from ctDNA 152, 155 . In the situation where the rearrangement is identified, fluorescence in situ hybridization (FISH) analysis of CTCs might be useful because it is easier to perform and provides information on intrapatient heterogeneity.
CNAs can be analysed from both CTCs and ctDNA. Remarkably, distinct copynumber profiles in patients with chemosensitive and chemorefractory SCLC could be identified through the analysis of CTCs sampled before the onset of treatment, providing clues about the molecular mechanisms that distinguish chemosensitive from chemorefractory disease 156 .
Resistance mechanisms are not only driven by genomic mechanisms. In melanoma, approximately 38% of tumour resistance to BRAFtargeted therapy can be attributed to nongenomic mechanisms and 56% to combined genomic and nongenomic aberrations 157 . Castrationresistant prostate cancer is the clinical entity in which geneexpression changes in CTCs have been most widely explored for assessment of treatment resist ance 158 to androgenblocking interventions, in particular increased expression of splice variant 7 of AR 159, 160 . CTC analysis at singlecell resolution revealed a high hetero geneity in prostate cancer cell transcriptomes and high lighted activation of the glucocorticoid receptor and noncanonical WNT signalling pathways in patients resistant to therapies inhibiting androgens 161 .
The role of phenotypic switching in drug resistance is gaining acceptance across many tumour entities such as lung cancers (NSCLC), breast cancers, prostate cancers, pancreatic cancers and melanomas 159, [162] [163] [164] [165] . Phenotypic switching to a less differentiated phenotype has been reported in CTCs in patients with melanoma relaps ing after a targeted therapy treatment 162 . Therefore, CTC analysis at singlecell resolution could fit into the dynamic exploration of these molecular mechanisms mostly driven at the RNA or proteomic level and would allow the adaptation of therapy in patients experiencing such resistance. In breast cancer, CTCs from patients with oestrogen receptor (ER) + and HER2breast cancer can interconvert to an HER2 + phenotype under cyto toxic treatment without acquisition of additional genetic aberrations 163 . These data were recently corroborated by evidence of 27% discordance in ER status and 23% discordance in HER2 status between CTCs and matched primary tumours 166 . CTCs in neuroendocrine prostate cancer have been described to bear a specific phenotype 88 and their detection as a potential resistance mechanism to endocrine therapy deserves further investigation. Finally, investigating the reversibility and the molecular mechanisms driving these phenotypic states is of utmost importance as this would offer new therapeutic strategies and new treatment regimens.
Functional studies on CTCs might provide fur ther clues about resistance mechanisms. Expansion of CTCs from patients as cell lines or CDXs 71, 167, 168 offers the unique opportunity to test drugs for personalized
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www.nature.com/nrc medicine. However, CTCderived cell lines or CDXs have been mainly derived from exceptional cases with very high CTC counts and development of both models takes many months 60, 62, 63 , which makes it as yet unsuitable for clinical use. The collection of large amounts of CTCs through DLA, in a viable state 169 or using in vivo CTC capture devices 150, 170 , might provide a future solution to this limitation (Box 5).
In order to implement LB assays in clinical routine, international assay standards need to be developed (for example, by the EU Innovative Medicines Initiative (IMI) consortium CANCERID or the European Liquid Biopsy Society (ELBS) in Europe and the Blood Profiling Atlas in Cancer (BloodPAC) consortium in the United States). Their clinical utility (that is, whether the decision made based on LB results in prolonged sur vival or another benefit for the patient) also needs to be demonstrated. The encouraging preliminary results of the STIC Metabreast study were recently reported: in patients with ER + and HER2metastatic breast cancers, for whom there are no objective criteria to choose between firstline hormone therapy or chemotherapy, high or low CTC counts can be used for choosing between chemother apy or hormone therapy, respectively 171 . There are also several ongoing clinical trials in which therapy decisions are based on the CTC phenotypic or molecular char acterization in different cancer entities (for example, DETECTIV in breast cancer 172 , CABAV7 in prostate cancer 173 ) but also on ctDNA detection (for example, TACTD in metastatic colorectal cancer 174 , cTRACKTN in the early stages of breast cancer 175 ).
Liquid biopsies in the era of immunotherapy. Immune checkpoint inhibitors have opened a new era in immuno therapy with exceptional longterm remissions and the most durable responses observed in melanoma and NSCLC 176, 177 . However, it is still difficult to pre dict response to these inhibitors, which have severe side effects and substantial costs. In this context, CTCs could be analysed for major histocompatibility complex (MHC) expression 178, 179 to assess whether tumour cell peptide antigens can be presented via MHC. In addi tion, T cell activity is blocked in many cancers via the PDL1-PD1 checkpoint axis, and the expression of PDL1 on tumour cells has been the main target for CTC analy ses, including clinical studies in breast cancer 180 , in NSCLC 181, 182 , in NSCLC after radio(chemo)therapy 183 or in head and neck carcinomas 184 . ctDNA monitoring is also useful to monitor tumour response to immuno therapy 185, 186 , and can help to decipher radiologic pseudo progression from real progression 187 . Mutational load is the main predictive biomarker assessed on ctDNA in the context of immunotherapies 188 , which is based on the view that high mutational load leads to high neoantigen expression and thereby efficient recognition of tumour cells by lymphocytes 189 .
Multidimensional analysis of CTCs at singlecell reso lution with the combined analysis of ctDNA and protein content could provide more information than the use of a single LB analyte. Especially, the analysis of CTCs, ctDNA or tumourderived EVs together with immune cells or immune cellderived EVs in the blood could be interesting approaches [190] [191] [192] . Additional populations of cells circulating in the bloodstream can be included, such as myeloidderived suppressor cells (MDSCs), which can inhibit antitumour T cell immunity [193] [194] [195] . Moreover, cir culating miRNAs may give additional information on response to immunotherapy 196 .
Conclusions and future perspectives
Singlecell technologies now allow a comprehensive analysis of CTCs to unravel diverse aspects of metastasis and resistance mechanisms to cancer therapy. CTC analy sis provides unique insights into tumour hetero geneity beyond genomic aberrations that are not covered by ctDNA analysis, such as transcriptional heterogeneity using singlecell RNA sequencing 95 . However, there are still numerous questions regarding the biology of CTCs that deserve future investigation. The biology of tumour dissemination creates substantial hetero geneity within CTCs depending on their different sites of origin (primary tumour, lymph node, metastatic sites), mode of migration (single cells or clusters) or metastasisinitiating capability. Moreover, different meta static sites in an individual patient might not present the same propensity of shedding tumour cells (or tumour DNA). Therefore, it is still unclear whether CTC (and ctDNA) analysis could lead to a potential biological bias with the overrepresentation of the most invasive clones releasing CTCs or the sites most actively shed ding DNA. Cellular barcoding in genetically engineered mouse models 197 , characterization of a larger amount of cells in DLA products 82 (Box 5) or autopsy studies might help to investigate to what extent CTC profiles reflect those of tumour tissues of the host. In the near future, it appears possible to simultaneously assess the genome and transcriptome with either the epigenome or epitope expression in the same single cell, expanding our ability to explore the connection between cellular genotypes and phenotypes 198, 199 , and to build multidimensional signatures that would embrace tumour complexity with more accuracy. Expanding our abilities to culture CTCs and develop xenografts in mice or other species such as zebrafish 72 would also allow us to obtain a more func tional view of heterogeneity and should help to design efficient therapeutic strategies.
Other plasma products such as cellfree miRNA or other types of noncoding RNA 9 , EVs 200 or tumour educated platelets 201 , with their abundance and (rela tively) easy isolation, represent an attractive strategy for the detection of cancer, and these analytes offer the opportunity to also identify tumourinduced changes in the microenvironment. These other LB analytes have been shown to be involved in many different aspects of tumour progression 9, 10, 202 , and as mediators of cellto cell communication they can also contribute to tumour heterogeneity. However, as EVs can be released by many types of cells into the circulation, the key challenge is to identify specific cell surface markers to discrimi nate EVs derived from either tumour or host cells. The analysis of the cargo of the different types of EVs might reveal important new insights into tumour-host inter actions, whereas the analysis of CTCs or ctDNA is more restricted to the tumour cells themselves.
Bioinformatics analysis is necessary to interpret the massive amount of data generated by different "omics" approaches 8, 203 , and machine learning methods (that is, artificial intelligence) have the potential to accel erate the development of biomarkers derived from LB analytes. Machine learning methods have already been applied to LB analytes, using logistic regression algo rithms in the CancerSEEK test 112 or neural networks to identify miRNA patterns to distinguish healthy women from those with ovarian cancer 204 . Regarding CTC analysis, the most advanced methods are dedi cated to the identification and sorting of the cells 205, 206 . By integrating feature extraction (including protein concentration, optical loss and numerous morpho logical features) and deep learning with highthroughput quantitative imaging, accurate differentiation of CTCs was achieved 207 . However, machine learning algorithms highly depend on the quantity and quality of data used to train the algorithm. Because of intratumour and intertumour heterogeneity, it becomes challenging to select a cohort that represents the entire range of tumour cell plasticity, which may lead to a nonnegligible risk of overfitting, a situation in which the model mimics the training data sets but cannot be generalized to new cases. Nevertheless, artificial intelligence will be required for development of multicomposite biomarkers derived from CTCs, host cells and blood plasma products including ctDNA, miRNAs, EVs or tumoureducated platelets.
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